BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PR Pharmaceuticals, Inc. Files IND For Pulmonary Hypertension


12/20/2005 10:36:52 AM

FORT COLLINS, Colo., Dec. 20 /PRNewswire/ -- PR Pharmaceuticals, Inc. (PRP), announced today that it filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the Company's first clinical product, PulmoLAR(TM) (2-methoxyestradiol) for the treatment of pulmonary arterial hypertension (PAH).

"This IND for PulmoLAR is a milestone for our company and an important step in our development of this novel therapy. The data that have and continue to be generated in animal models of PAH and other cardiovascular injury lend strong support to this development initiative. Recently, we've generated a considerable body of important safety information that encourage us to begin human studies with our proprietary low-volume, sustained-release injectable formulation," said Dr. Claude Piche, PRP's Vice President of Clinical Development and Regulatory Affairs.

Stevan P. Tofovic, M.D., Ph.D., Assistant Professor at the University of Pittsburgh School of Medicine and principal investigator on the use of PulmoLAR in animal models of PAH, stated, "Our work in numerous animal models of cardiovascular injury, and in models of PAH in particular, indicates treatment with PulmoLAR has a dramatic effect in improving survival, reducing the damage to the arteries of the lungs and preventing subsequent right heart failure. We've also shown reduced injury and significant improvements in survival in a recently completed study in an animal model of PAH in which we compared 2-methoxyestradiol to some of the leading drugs used to treat PAH in humans. These results are very encouraging and we are excited to see PulmoLAR progress to clinical testing."

About PulmoLAR(TM)

The active ingredient in PulmoLAR is 2-methoxyestradiol (2ME), an endogenous, non-estrogenic metabolite of estradiol. 2ME has multiple mechanisms of action, many of which are particularly relevant to PAH. In vitro studies have demonstrated 2ME reduces endothelial cell production of endothelin-1 and increases synthesis of prostacyclin. 2ME is also a potent antiproliferative agent. PulmoLAR is PRP's proprietary, sustained-release, injectable formulation. Animal studies conducted to date suggest a single, low-volume injection may provide therapeutic levels of drug for one month or more. In April 2005, Orphan Drug Status designation was granted by the FDA for use of PulmoLAR for the treatment of pulmonary arterial hypertension.

About PR Pharmaceuticals, Inc.

PR Pharmaceuticals, Inc. (PRP) is a privately held biopharmaceutical company focused on developing, manufacturing and commercializing bioactive compounds in sustained-release formulations. The Company specializes in injectable, biodegradable formulations and has a significant intellectual property position in the encapsulation of large molecules such as proteins and peptides as well as encapsulation of classic small molecules into biodegradable microparticles. PRP is applying compelling and patented technology to create a diverse range of candidate pharmaceutical products to address unmet medical needs.

PulmoLAR(TM) is a trademark of PR Pharmaceuticals, Inc.

PR Pharmaceuticals, Inc.

CONTACT: Dr. Claude Piche of PR Pharmaceuticals, Inc., +1-970-484-5560



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES